Detalhe da pesquisa
1.
Inhibition of structural joint damage progression with upadacitinib in rheumatoid arthritis: 1-year outcomes from the SELECT phase 3 program.
Rheumatology (Oxford)
; 61(8): 3246-3256, 2022 08 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-34897366
2.
CSF1 receptor inhibition of tenosynovial giant cell tumor using novel disease-specific MRI measures of tumor burden.
Future Oncol
; 18(12): 1449-1459, 2022 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-35040698
3.
Long-term outcomes of pexidartinib in tenosynovial giant cell tumors.
Cancer
; 127(6): 884-893, 2021 03 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-33197285
4.
Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial.
Lancet
; 394(10197): 478-487, 2019 08 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-31229240
5.
Safety and effectiveness of upadacitinib or adalimumab plus methotrexate in patients with rheumatoid arthritis over 48 weeks with switch to alternate therapy in patients with insufficient response.
Ann Rheum Dis
; 78(11): 1454-1462, 2019 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-31362993
6.
Phase IIa, placebo-controlled, randomised study of lutikizumab, an anti-interleukin-1α and anti-interleukin-1ß dual variable domain immunoglobulin, in patients with erosive hand osteoarthritis.
Ann Rheum Dis
; 78(3): 413-420, 2019 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-30552176
7.
Structure-Guided Blockade of CSF1R Kinase in Tenosynovial Giant-Cell Tumor.
N Engl J Med
; 373(5): 428-37, 2015 Jul 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-26222558
8.
Short-term changes on MRI predict long-term changes on radiography in rheumatoid arthritis: an analysis by an OMERACT Task Force of pooled data from four randomised controlled trials.
Ann Rheum Dis
; 76(6): 992-997, 2017 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-27974302
9.
Abatacept reduces disease activity and ultrasound power Doppler in ACPA-negative undifferentiated arthritis: a proof-of-concept clinical and imaging study.
Rheumatology (Oxford)
; 56(1): 58-67, 2017 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28028155
10.
Repeatability and response to therapy of dynamic contrast-enhanced magnetic resonance imaging biomarkers in rheumatoid arthritis in a large multicentre trial setting.
Eur Radiol
; 27(9): 3662-3668, 2017 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-28116513
11.
Sustained improvements in MRI outcomes with abatacept following the withdrawal of all treatments in patients with early, progressive rheumatoid arthritis.
Ann Rheum Dis
; 75(8): 1501-5, 2016 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-26865601
12.
MRI assessment of suppression of structural damage in patients with rheumatoid arthritis receiving rituximab: results from the randomised, placebo-controlled, double-blind RA-SCORE study.
Ann Rheum Dis
; 75(1): 170-7, 2016 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-25355728
13.
Maintenance of remission following 2 years of standard treatment then dose reduction with abatacept in patients with early rheumatoid arthritis and poor prognosis.
Ann Rheum Dis
; 74(3): 564-8, 2015 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-25550337
14.
The effects of tocilizumab on osteitis, synovitis and erosion progression in rheumatoid arthritis: results from the ACT-RAY MRI substudy.
Ann Rheum Dis
; 73(5): 810-6, 2014 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-24525910
15.
Long-term safety and efficacy of upadacitinib versus adalimumab in patients with rheumatoid arthritis: 5-year data from the phase 3, randomised SELECT-COMPARE study.
RMD Open
; 10(2)2024 May 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-38806190
16.
MRI comes of age in RA clinical trials.
Ann Rheum Dis
; 72(6): 794-6, 2013 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-23345597
17.
Impact of intravenous abatacept on synovitis, osteitis and structural damage in patients with rheumatoid arthritis and an inadequate response to methotrexate: the ASSET randomised controlled trial.
Ann Rheum Dis
; 72(8): 1287-94, 2013 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-22915624
18.
Can flare be predicted in DMARD treated RA patients in remission, and is it important? A cohort study.
Ann Rheum Dis
; 71(8): 1316-21, 2012 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-22294638
19.
Sustained inhibition of progressive joint damage with rituximab plus methotrexate in early active rheumatoid arthritis: 2-year results from the randomised controlled trial IMAGE.
Ann Rheum Dis
; 71(3): 351-7, 2012 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-22012969
20.
An oral Syk kinase inhibitor in the treatment of rheumatoid arthritis: a three-month randomized, placebo-controlled, phase II study in patients with active rheumatoid arthritis that did not respond to biologic agents.
Arthritis Rheum
; 63(2): 337-45, 2011 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-21279990